Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

31.98
+1.725.68%
Post-market: 32.230.2500+0.78%19:58 EDT
Volume:1.07M
Turnover:33.72M
Market Cap:2.37B
PE:484.28
High:32.15
Open:30.19
Low:30.04
Close:30.26
Loading ...

Stock Track | Kiniksa Pharmaceuticals Soars 5% on Strong Q2 Earnings and Raised Guidance

Stock Track
·
Yesterday

Just The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% Run

Blockhead
·
Yesterday

Why Kiniksa Pharmaceuticals (KNSA) Is Up 12.5% After Reporting Q2 Profitability and Raising Revenue Guidance

Simply Wall St.
·
01 Aug

Kiniksa Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
30 Jul

Kiniksa price target raised to $54 from $45 at Jefferies

TIPRANKS
·
30 Jul

Kiniksa Pharma Shares Climb After Swinging to 2Q Profit, Posting Higher Sales

Dow Jones
·
29 Jul

Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-market on Strong Q2 Results and Raised Revenue Guidance

Stock Track
·
29 Jul

Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-Market on Q2 Earnings Beat and Raised 2025 Guidance

Stock Track
·
29 Jul

Kiniksa Pharmaceuticals Q2 EPS USD 0.24

Reuters
·
29 Jul

Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q2 EPS $0.23, vs. FactSet Est of $0.22

MT Newswires Live
·
29 Jul

Kiniksa Pharmaceuticals' ARCALYST 2025 Expected Net product Revenue Guidance Increased To $625M-$640M Compared To Prior Guidance Of $590M-$605M

Benzinga
·
29 Jul

Kiniksa Pharmaceuticals Q2 2025 EPS $0.23 Beats $0.18 Estimate, Sales $156.797M Beat $145.218M Estimate

Benzinga
·
29 Jul

Kiniksa Pharmaceuticals Reports 52% Increase in ARCALYST Q2 Net Product Revenue, Achieves $17.8M Net Income

Reuters
·
29 Jul

Kiniksa Pharmaceuticals International: Kpl-387 Phase 2/3 Clinical Trial in Recurrent Pericarditis Initiated; Phase 2 Data Expected in 2H 2026

THOMSON REUTERS
·
29 Jul

Kiniksa Pharmaceuticals International Plc - Arcalyst 2025 Net Product REV Guidance Raised to $625-$640 Mln

THOMSON REUTERS
·
29 Jul

Kiniksa Pharmaceuticals International Plc: Expects 2025 Arcalyst Net Product Revenue of Between $625 Mln and $640 Mln

THOMSON REUTERS
·
29 Jul

Kiniksa Pharmaceuticals International PLC expected to post earnings of 18 cents a share - Earnings Preview

Reuters
·
25 Jul

Goldman Sachs Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
18 Jul

Chief Operating Officer Eben Tessari Reports Disposal of Kiniksa Pharmaceuticals Common Shares

Reuters
·
17 Jul

Kiniksa Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
09 Jul